Posts Tagged ‘Amgen’

Shared Investigator Platform (SIP) Strengths And Struggles

At any given time, a principal investigator (PI) can be working on one or more studies for a single sponsor company, or multiple studies for multiple sponsors. Likewise, each sponsor runs its clinical trials its own way, using its preferred technology and processes. And, often times, the technology and/or processes differ from study to study, […]

How Pharma Executives View Drug Pricing

The cost and affordability of drugs has been a central theme permeating the pharmaceutical industry for decades. Drugs are believed to be too expensive for patients to cover at the counter, even for those who are insured. The sentiment shared is by both Republicans and Democrats. The high cost of drugs can have significant repercussions, […]

FDA Building Sign

The Case For A Reformed FDA

Life sciences is one of the most heavily regulated industries in the United States. It takes 10 to 15 years and an average of $2.6 billion for a drug to reach pharmacy shelves. Stringent regulations formed by the FDA are major factors for the lengthy timelines and high costs, sometimes preventing people from receiving potentially […]

Why Pharma Execs Want A More Favorable Tax Climate

The idea of companies moving their businesses to other parts of the world to benefit from lower taxes is not new. Allergan, the maker of Botox® and other drugs, transferred its global headquarters from New Jersey to Ireland in 2013. Medtronic moved its headquarters to Ireland in 2015, once it completed the acquisition of Covidien, […]

[Guide] The State Of The Life Sciences Industry

Last year’s presidential election invoked a great deal of angst in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While the things candidates said they would do could very well be different from what they might actually do, their words and records were enough […]